AKBM logo

Aker BioMarine ASA Stock Price

OB:AKBM Community·NOK 9.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 12 Fair Values set on narratives written by author

AKBM Share Price Performance

NOK 0
-78.80 (-100.00%)
NOK 124.91
Fair Value
NOK 0
-78.80 (-100.00%)
Price NOK 0

AKBM Community Narratives

·
Fair Value NOK 124.91 15.1% undervalued intrinsic discount

Analysts Lift Aker BioMarine Price Target on Improved Profit Margins and Key Customer Win

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
·
Fair Value NOK 75.11 41.1% overvalued intrinsic discount

Sustainable Demand Will Redefine Marine Omega-3 Nutrition

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value NOK 48.4 119.0% overvalued intrinsic discount

Rising Regulations And High Capital Demands Will Cripple Krill Supply

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
NOK 48.4
119.0% overvalued intrinsic discount
Profit Margin
15.25%
Future PE
11.17x
Price in 2028
NOK 58.44
NOK 75.11
41.1% overvalued intrinsic discount
Profit Margin
15%
Future PE
15.47x
Price in 2028
NOK 90.4

Trending Discussion

No trending discussion available.

Updated Narratives

AKBM logo

AKBM: Higher Margin Contract Wins Will Support Stronger Future Upside

Fair Value: NOK 124.91 15.1% undervalued intrinsic discount
8 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AKBM logo

Rising Regulations And High Capital Demands Will Cripple Krill Supply

Fair Value: NOK 48.4 119.0% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AKBM logo

Sustainable Demand Will Redefine Marine Omega-3 Nutrition

Fair Value: NOK 75.11 41.1% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

High growth potential with mediocre balance sheet.

0 Risks
2 Rewards

Aker BioMarine ASA Key Details

US$227.2m

Revenue

US$124.9m

Cost of Revenue

US$102.3m

Gross Profit

US$112.3m

Other Expenses

-US$10.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 29, 2026
-0.11
45.03%
-4.40%
150.7%
View Full Analysis

About AKBM

Founded
2006
Employees
258
CEO
Matts Johansen
WebsiteView website
www.akerbiomarine.com

Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LYSOVETA brand; and marine-origin DHA omega-3 from microalgae under the Revervia brand name, as well as advanced phospholipid technology under PL+ name. The Consumer Health Products segment sells processed and packaged krill, fish, and plants derived raw materials to retailers in the United States. The Emerging Business segment offers krill oil under Kori brand name. The company provides protein solutions under the Understory brand; biostimulants under KRBNX brand; and a therapeutic candidate based on omega-3 to manage and treat cardiometabolic diseases under CaPre brand name, as well as delivers circular products utilizing recycled industrial and marine plastic waste under AION name. Aker BioMarine ASA was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.

Recent AKBM News & Updates

Narrative Update Jun 23

AKBM: Higher Margin Contract Wins Will Support Stronger Future Upside

Analysts have slightly lowered their price target for Aker BioMarine to NOK 124.91, reflecting modestly revised assumptions around long term revenue growth, profit margins, and a somewhat lower future P/E multiple. What's in the News for Aker BioMarine Aker BioMarine ASA secured a new contract for the supply of Lysoveta, with a contract value of about US$4 million in 2026 and expectations for higher volumes in 2027, according to a client announcement.

Recent updates

No updates